These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

72 related articles for article (PubMed ID: 11596402)

  • 1. [Acquired autoimmune myasthenia gravis].
    Takamori M
    Ryoikibetsu Shokogun Shirizu; 2001; (36):323-35. PubMed ID: 11596402
    [No Abstract]   [Full Text] [Related]  

  • 2. Anti-ryanodine receptor-positive acetylcholine receptor-negative myasthenia gravis: evidence of impaired excitation-contraction coupling.
    Imai T; Tsuda E; Toyoshima T; Yoshikawa H; Motomura M; Shimohama S
    Muscle Nerve; 2011 Feb; 43(2):294-5. PubMed ID: 21254099
    [No Abstract]   [Full Text] [Related]  

  • 3. [Myasthenia gravis].
    Kawaguchi N; Hattori T
    Nihon Rinsho; 2005 May; 63 Suppl 5():416-21. PubMed ID: 15954385
    [No Abstract]   [Full Text] [Related]  

  • 4. In silico study of potential autoimmune threats from rotavirus infection.
    Sarkar T; Das S; Nandy P; Bhowmick R; Nandy A
    Comput Biol Chem; 2014 Aug; 51():51-6. PubMed ID: 24929545
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Responses in vitro of peripheral blood lymphocytes from patients with myasthenia gravis to stimulation with human acetylcholine receptor alpha-chain peptides: analysis in relation to age, thymic abnormality, and ethnicity.
    Oshima M; Deitiker PR; Mosier DR; Smith RG; Atassi MZ
    Hum Immunol; 2005 Jan; 66(1):32-42. PubMed ID: 15620460
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ryanodine receptor antibodies in myasthenia gravis: epitope mapping and effect on calcium release in vitro.
    Skeie GO; Mygland A; Treves S; Gilhus NE; Aarli JA; Zorzato F
    Muscle Nerve; 2003 Jan; 27(1):81-9. PubMed ID: 12508299
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Striational antibodies in myasthenia gravis: reactivity and possible clinical significance.
    Romi F; Skeie GO; Gilhus NE; Aarli JA
    Arch Neurol; 2005 Mar; 62(3):442-6. PubMed ID: 15767509
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Progress in the field of neurology in the last 100 years: Myasthenia gravis].
    Takamori M
    Nihon Naika Gakkai Zasshi; 2002 Aug; 91(8):2354-61. PubMed ID: 12373848
    [No Abstract]   [Full Text] [Related]  

  • 9. [Thymectomy and muscle antibodies in myasthenia gravis].
    Romi F; Gilhus NE; Aarli JA
    Tidsskr Nor Laegeforen; 2004 Mar; 124(5):629-31. PubMed ID: 15004605
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Myasthenia gravis.
    Sen S; Banerjee TK
    J Assoc Physicians India; 1995 Jul; 43(7):487-93. PubMed ID: 8713224
    [No Abstract]   [Full Text] [Related]  

  • 11. [Juvenile myasthenia gravis].
    Ohno K; Sahashi K
    Ryoikibetsu Shokogun Shirizu; 2001; (36):340-3. PubMed ID: 11596404
    [No Abstract]   [Full Text] [Related]  

  • 12. Autoimmune myasthenia gravis in childhood.
    Andrews PI
    Semin Neurol; 2004 Mar; 24(1):101-10. PubMed ID: 15229797
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Unravelling the pathogenesis of myasthenia gravis.
    Vincent A
    Nat Rev Immunol; 2002 Oct; 2(10):797-804. PubMed ID: 12360217
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Adult onset acquired myasthenia gravis in three Great Dane littermates.
    Kent M; Glass EN; Acierno M; Shelton GD
    J Small Anim Pract; 2008 Dec; 49(12):647-50. PubMed ID: 18684140
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Myasthenia gravis].
    Suzumura A
    Ryoikibetsu Shokogun Shirizu; 2000; (31):20-3. PubMed ID: 11269057
    [No Abstract]   [Full Text] [Related]  

  • 16. [Ocular myasthenia: a diagnostic and management challenge--a review].
    Langmann A; Lindner S; Koch M; Diez J
    Klin Monbl Augenheilkd; 2004 Feb; 221(2):77-86. PubMed ID: 14986204
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Myasthenia gravis and its immunological aspects].
    Kinoshita M; Okada S; Oyamatu T; Iguchi H
    No To Shinkei; 1993 Oct; 45(10):909-16. PubMed ID: 8268030
    [No Abstract]   [Full Text] [Related]  

  • 18. Novel immunotoxin: a fusion protein consisting of gelonin and an acetylcholine receptor fragment as a potential immunotherapeutic agent for the treatment of Myasthenia gravis.
    Hossann M; Li Z; Shi Y; Kreilinger U; Büttner J; Vogel PD; Yuan J; Wise JG; Trommer WE
    Protein Expr Purif; 2006 Mar; 46(1):73-84. PubMed ID: 16230023
    [TBL] [Abstract][Full Text] [Related]  

  • 19. On the initial trigger of myasthenia gravis and suppression of the disease by antibodies against the MHC peptide region involved in the presentation of a pathogenic T-cell epitope.
    Atassi MZ; Oshima M; Deitiker P
    Crit Rev Immunol; 2001; 21(1-3):1-27. PubMed ID: 11642597
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Coexistence of myasthenia gravis and serological markers of neurological autoimmunity in neuromyelitis optica.
    McKeon A; Lennon VA; Jacob A; Matiello M; Lucchinetti CF; Kale N; Chan KH; Weinshenker BG; Apiwattinakul M; Wingerchuk DM; Pittock SJ
    Muscle Nerve; 2009 Jan; 39(1):87-90. PubMed ID: 19086079
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.